Field of the Invention Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists ("MRA") and at least one additional active ingredient selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or mixtures thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided. Background of the Invention Muscarinic receptors, members of the G Protein Coupled Receptors (GPCRs), are composed of a family of 5 receptor sub-types (M1, M2, M3, M4 and M5) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented. For example, the M1 subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia, the M2 subtype is present primarily in the heart where it mediates cholinergically induced bradycardia, and the M3 subtype is located primarily on smooth muscle and salivary glands (Nature, 323, p.411 (1986); Science, 237, p.527 (1987)). The biological potentials of modulating muscarinic receptor subtypes by ligands in different disease conditions, such as Alzheimer's Disease, pain, urinary disease condition, chronic obstructive pulmonary disease, and the like, are described (Current Opinions in Chemical Biology, 3, p. 426 (1999), as well as in Trends in Pharmacological Sciences, 22, p. 409 (2001) by Eglen et al). Therapeutic opportunities for muscarinic receptors in the central nervous system and elaborates on muscarinic receptor structure and function, pharmacology and their therapeutic uses are described (J. Med. Chem., 43, p. 4333 (2000), by Felder et al). The pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists are described (Molecules, 6, p. 142 (2001)). The recent developments on the role of different muscarinic receptor subtypes using different muscarinic receptor of knock out mice are described (Birdsall et al, Trends in Pharmacological Sciences, 22, p. 215 (2001)). Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, making it difficult to assign specific functions to the individual receptors. Although classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc. Subsequent development of the quarterly derivatives of atropine such as ipratropium bromide are better tolerated than parenterally administered options, but most of these are not ideal anti-cholinergic bronchodilators, due to lack of selectivity for muscarinic receptor sub-types, resulting in dose-limiting side-effects such as thirst, nausea, mydriasis and those associated with the heart such as tachycardia mediated by the M2 receptor. The pharmacology of the lower urinary tract infections are described (Annual Review of Pharmacological Toxicol., 41, p. 691 (2001)). Although anti-muscarinic agents, such as oxybutynin and Tolterodine, which act non-selectively on muscarinic receptors have been used for many years to treat bladder hyperactivity, the clinical effectiveness of these agents has been limited due to side effects such as dry mouth, blurred vision and constipation. Tolterodine is considered to be generally better tolerated than oxybutynin. (Steers et al, in Curr. Opin. Invest. Drugs, 2, 268; Chappie et al, in Urology, 5_5, 33; Steers et al., Adult and Pediatric Urology, ed. Gillenwatteret al., pp 1220-1325, St. Louis, MO; Mosby. 3rd Edition (1996)). Compounds having antagonistic activity against muscarinic receptors have been described in Japanese patent application Laid Open Number 92921/1994 and 135958/1994; WO 93/16048; U.S. Patent No. 3,176,019; GB 940,540; EP 0325 571; WO 98/29402; EP 0801067; EP 0388054; WO 9109013; U.S. Patent No. 5,281,601. Also, U.S. Patent Nos. 6,174,900, 6,130,232 and 5,948,792; WO 97/45414 describes 1,4-disubstituted piperidine derivatives; WO 98/05641 describes fluorinated, 1,4-disubstitued piperidine derivatives; and WO 93/16018 and W096/33973 are other related references. U.S. Patent No. 5,397,800 discloses l-azabicyclo[2.2.1]heptanes. U.S. Patent No. 5, 001,160 describes 1-aryl-l -hydroxy-1-substituted-3 -(4-substituted-l -piperazinyl)-2-propanones. WO 01/42213 describes 2-biphenyl-4-piperidinyl ureas. WO 01/42212 describes carbamate derivatives. WO 01/90081 describes amino alkyl lactam. WO 02/53564 describes novel quinuclidine derivatives. WO 02/00652 describes carbamates derived from arylalkyl amines. WO 02/06241 describes l,2,3,5-tetrahydrobenzo(c)azepin-4-one derivatives. A report in J. Med. Chem., 44, p. 984 (2002), describes cyclohexylmethyl piperidinyl triphenylpropioamide derivatives as selective M3 antagonist discriminating against the other receptor subtypes. However in view of the above, there remains a need for novel highly selective muscarinic receptor antagonists that can interact with distinct subtypes while avoiding the occurrence of adverse effects. Summary of the Invention In one general aspect, provided are pharmaceutical compositions comprising one or more muscarinic receptor antagonists ("MRA") and at least one additional active ingredient selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. Suitable MRA can be one or more compounds having the structures of Formula I, II, or III, wherein: a. Formula I i(Formula Removed)) Formula I or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein Ar represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, sulphur or nitrogen, wherein the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4), N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; R1 represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g., fluorine, chlorine, bromine and iodine); R2 represents alkyl, (C3-C7) cycloalkyl ring, (C3-C7) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (CrC4) or N-aryl amino, amino carbonyl, N- lower alkyl (C1-C4) or N-aryl amino carbonyl; W represents (CH2)P, wherein p represents 0 to 1; X represents oxygen, sulphur, -NR or no atom (i.e., a bond), wherein R represents hydrogen or (C1-6) alkyl; Y represents CHR5CO or (CH2)q, wherein R5 represents hydrogen or methyl, and q represents 0 to 4; Z represents oxygen, sulphur, or NR10, wherein R10 represents hydrogen, or C1-6 alkyl; Q represents (CH2)n, CHRg or CH2CHR9, wherein n represents 0 to 4, R8 represents H, OH, C1-6, alkyl, C1-6 alkenyl, or C1-6 alkoxy, and R9 represents H, OH, lower alkyl (C1-C4) or lower alkoxy (C1-C4); R6 and R7 are independently selected from H, CH3, COOH, CONH2, NH2 or CH2NH2; and R4 represents hydrogen or C1-C15 saturated or unsaturated aliphatic hydrocarbon group, wherein 1 to 6 hydrogen atoms of C1-C15 saturated or unsaturated aliphatic hydrocarbon group may be substituted with a group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms independently selected nitrogen, oxygen or sulphur, and any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl, heteroarylalkenyl may be optionally substituted with lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhaloalkoxy (C1-C4), unsubstituted amino, N-lower alkylamino (C1-C4), or N-lower alkylamino carbonyl (C1-C4); b. Formula II is: c or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein R1' and R2' are independently selected from C1-C6 alkyl, C3-C7 cycloalkyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; and Z' represents oxygen or NR.3; wherein R3 represents hydrogen or C1-C3 alkyl; c. Formula III is, (Formula Removed) or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein Ri" and R2" are independently selected from Ci-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; R3' represents Ci-C6 alkyl, wherein 1 -3 hydrogen atom(s) may be substituted with a group independently selected from C5-C7 cycloalkyl, l,3-dioxo-l,3-dihydro-isoindolyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected C1-C4 alkyl or halogen; and Z represents oxygen or NR4', wherein R4' represents hydrogen or C1-C3 alkyl. Pharmaceutical compositions described herein can include one or more of the following compounds of Formula I, II and Formula III, for example: (la.5a.6a)-N-[3-benzyl-3-azabicyclo[3.1.0Jhexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 1), (la.5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Comp No. 2), (1 a,5a.6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 3). (la.5a.6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 4), (la.5a.6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 5) (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 6), (la,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 7), (la,5a.6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 8), (la.5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2- phenyl acetamide (Compound No. 9), (la.5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2- phenyl acetamide (Compound No. 10), (la.5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cycIopentyl-2-phenyl acetate (Compound No. 11), (la,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 12), (I a,5a.6a)-N-[3-(2-(3,4-methy!enedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2- phenyl acetamide (Compound No. 13), (la,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2- phenyl acetamide (Compound No. 14), (la,5a.6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-pheny! acetamide (Compound No. 15), (la.5a.6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 16), (la,5a,6a)-l3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 17). (la.5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 18), (la,5a,6a)-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 19). (la,5a,6a)-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Comp No. 20), (la,5a.6a)-N-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 21), (la,5a.6a)-N-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 22), (la,5a.6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(l-aminoethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Comp No. 23), (1 a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-( 1 -aminoethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Comp No. 24), (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(l-aminoethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 25), (la,5a.6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 26). (la,5a.6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 27), (2R)-(+)- (1 a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 28), (2R)-( + )- (la.5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 29), (2R) (+)-(la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 30). (2R) (+)-(la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Comp No. 31), (2S)-(-)- (la.5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyI)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 32), (2S)-(-)-(la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Comp No. 33), (la.5a.6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt (Compound No. 34), (2R)-(+)- (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 35), (2R)-(+)- (1 a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L-( + (-tartrate salt (Compound No. 36), (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Comp No. 37), (1 a.5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopropyl-2-phenyl acetamide (Comp No. 38), (1 a.5a.6a)-N-[ 3-(3-methyl-2-butenyl)-3-azabicyclo[3.1,0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 39), (I a.5a.6a)-[ 3-(3.4- methylenedioxyphenyl)methyl-3-azabicyclo[3.1,0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 40), (la.5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L-(+)-tartrate salt (Compound No. 41), (la,5a.6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2 diphenyl acetate L(+)-tartrate salt (Compound No. 42), (la,5a.6a)- [3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cycIohexyl-2-phenyl acetate L(+)-tartrate salt (Compound No. 43), (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt (Compound No. 44), (la.5a.6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 45), (la,5a.6a)-N-[3-(4-pyridylmethyi)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 46), (la.5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.01hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 47), (la,5a.6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide(Compound No. 48), (la,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 49). (la,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.01hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 50). (1 a.5a.6a)-N-|3-(2-pyridylmethyl)-3-azabicyclo[3.1,0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 51). (1 a,5a.6a)-N-l3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-ylJ-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 52), (1 a.5a.6a)-N-[3-(3-pyridy!methyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 53), (la.5a,6a)-N-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 54), (la,5a,6a)-N-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2- phenyl acetamide (Compound No. 55), (1 a,5a.6a)-N-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2- phenyl acetamide (Compound No. 56), (la,5a.6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 57), (1 a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 58), (la,5a,6a)-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 59), (la,5a.6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide .hydrochloride salt (Compound No. 60), (la.5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L(-) malic acid salt (Compound No. 61), (la,5a.6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. maleate salt (Compound No. 62), (2R.2S) (la,5a.6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Comp No. 63), (2R.2S) (la,5a.6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 64), (2R)-(la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide (Compd No. 65), (2R)-( 1 a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound No. 66), (2S)-( 1 a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide (Compound No. 67), (2S)-(la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound No. 68), (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide (Comp No. 69), (2R. 2S) (la,5a.6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide (Comp No. 70). (2R. 2S) (la.5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Comp No. 71). (2R. 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide tartarate salt (Compound No. 72), (2R) (la,5a,6a)-N-[3-azabicyclo[3.l.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound No. 73), (2R, 2S) (1 a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyi)-2-phenyl acetamide (Compound No. 74), (2R, 2S) (la.5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound No. 75), (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound No. 76), (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 77), (2R, 2S) (1 a,5a.6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 78), (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Comp No. 79), (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl)-2-cyclopentyl-2-hydroxy-N-niethyl-2-phenyl acetamide (Comp No. 80), N-[(la. 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 81), N-|(la. 5a, 6a)-3-azabicyclo[3.l.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide tartarate salt (Compound No. 82), (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide (Compound No. 83), (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide hydrochloride salt (Compound No. 84), (2R. 2S)-N-f(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenyl acetamide (Compound No. 85), (2R. 2S)-l(la. 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetic acid (Compound No. 86). (2R)-N-f(la. 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Comp No. 87), (2R)-N-[(la. 5a, 6a)-3-azabicyclo[3.1,0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 88), (2R. 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 89), (2R, 2S)-[( la. 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 90), (2R. 2S)-[(la. 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 91), (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetamide (Compound No. 92), (2R)-N-[(la. 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-(N-methyl) phenylacetamide (Comp No. 93), (2R, 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(m-methylphenyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 94). (2R. 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-y]-methyi]-2-(p-fluorophenyl)-2-hydroxy-2-phenylacetamide (Comp No. 95), (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-phenylacetamide (Comp No. 96), (2R)-N-[( 1 a, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 97), (2R)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 98), (2R, 2S) (la, 5a, 6a)-N- {-[4-(l,3-dioxo-l, 3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo [3.1.0] hex-6-yl-methyl}-2-hydroxy-2- cyclopentyl-2-phenylacetamide (Compound No. 99), (2R) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopent-l-enyl-2-phenylacetamide (Compound No. 100), (2R, 2S) (la. 5a, 6a)-N-(3-Isopropyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 101), (2R. 2S) (la, 5a, 6a)-N-(3-Diphenylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 102), (2R. 2S) (la, 5a, 6a)-N-(3-sec-butyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 103). (2R. 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-pentyl)-2-phenylacetamide (Compound No. 104). (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-2-(4-methoxyphenyl) acetamide (Compound No. 105), (la. 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-(N-ethyl)-2-phenylacetamide (Comp No. 106), (2R. 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-ethyl)-2-phenylacetamide (Compound No. 107), (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-(N-ethyl)-2-phenylacetamide (Compound No. 108), (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)- 2-hydroxy-2-(3-pentyl)-(N-methyl)-2-phenylacetamide (Compound No. 109), (2R, 2S) (la. 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(sec-butyl)-(N-methyl)-2-phenylacetamide (Compound No. 110), (2R. 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-(N-methyl)-2-phenylacetamide (Compound No. Ill), (2R, 2S) (la, 5a. 6a)-N-[3-(4-tert-butyl-benzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 112), (2R. 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohex-2-enyl-2-phenylacetamide (Compound No. 113), (la. 5a. 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 114), (2R, 2S) (la, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 115), (2R, 2S) (la, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyi-2-phenylacetamide (Compound No. 116), (la. 5a. 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 117), (la, 5a. 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0|hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 118), (2R. 2S) (la. 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 119), (2R, 2S) (la. 5a, 6a)-N-[2-(2.4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 120), (la, 5a. 6a)-N-[3-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 121), (2R, 2S) (la, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yI-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 122), (2R, 2S) (la, 5a. 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-2-phenylacetamide (Compound No. 123), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-(N-methyl)-2- phenylacetamide (Compound No. 124), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 125). (2R, 28) (la. 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenyl acetic acid ester (Compound No. 126), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-(N-methyl)-2- phenylacetamide (Compound No. 127), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenylacetamide (Compound No. 128), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-(N-methyl)-2- phenylacetamide (Compound No. 129), (2R. 2S) (la, 5a. 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyi)-2-hydroxy-2-(3-methylphenyl)-2-phenyl acetic acid ester (Compound No. 130), (2R. 28) (la, 5a. 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester (Compound No. 131), (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester tartarate salt (Compound No. 132), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide (Compound No. 133), (2R. 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide tartarate salt (Compound No. 134), (la. 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2,2-di(4-fluorophenyl)acetic acid ester (Compound No. 135). (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-di(4-fluorophenyl)-acetamide (Compound No. 136), (2R, 2S) (la. 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclobutyl-2-phenyl acetic acid ester (Compound No. 137), (2R, 2S) (la, 5a, 6a)-N-(3-cyclohexylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 138), (2R) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-methyl)-2-phenylacetamide (Compound No. 139), (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-(4-methylphenyl) acetamide (Compound No. 140), (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-2-(4-methylphenyl) acetic acid ester (Compound No. 141), (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-2-phenyl acetic acid ester (Compound No. 142). (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-methyl-2-phenyl acetamide (Compound No. 143). (2R. 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-2-phenyl acetic acid ester (Compound No. 144). (la, 5a. 6a)-N-(3-methyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-phenyl-(N-methyl)-2-phenylacetamide (Compound No. 145). (la. 5a. 6a)-N- (3-benzyl-3-azabicyclo [3.1.0] hex-6-yl-methyl]-2-hydroxy-2, 2-di (3-methylphenyl) acetamide (Compound No. 146), (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-(3-pentyl)-2-phenyl acetic acid ester (Compound No. 147). (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-(N-methyl)-2-phenylacetamide (Compound No. 148), N-|( la.5a,6a)-3-azabicyclo[3.1.0.]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide hydrochloride (Compound No. 149). or Tartarate salt of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)2-thienylacetate (Compound No. 150). In another general aspect there is provided methods of treating or preventing autoimmune, inflammatory, or allergic diseases or disorders, which comprises administering to a mammal in need thereof a pharmaceutical composition comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. Suitable MRA are one or more compounds having the structures of Formula I, II, or III as defined above. Detailed Description of the Invention In one aspect, there is provided pharmaceutical compositions comprising one or more muscarinic receptor antagonists ("MRA") and at least one additional active ingredients selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents MRA described herein include compounds having the structures of Formula I, II, or III, wherein Formula I is: (Formula Removed) acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein Ar represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, sulphur or nitrogen, wherein the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4), N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; Ri represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g., fluorine, chlorine, bromine and iodine); R2 represents alkyl, (C3-C7) cycloalkyl ring, (C3-C7) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4) or N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; W represents (CH2)P, wherein p represents 0 to 1; X represents oxygen, sulphur, -NR or no atom (i.e., a bond), wherein R represents hydrogen or (Ci-6) alkyl; Y represents CHR5CO or (CH2)q, wherein R5 represents hydrogen or methyl, and q represents 0 to 4; Z represents oxygen, sulphur, or NR10, wherein Rio represents hydrogen, or C|.6 alkyl; Q represents (CH2)n, CHR8 or CH2CHR9, wherein n represents 0 to 4, R8 represents H, OH, C1.6, alkyl, C1-6 alkenyl, or Ci-6 alkoxy, and R9 represents H, OH, lower alkyl (C1-C4) or lower alkoxy (C1-C4); R6 and R7 are independently selected from H, CH3, COOH, CONH2, NH2 or CH2NH2; and R4 represents hydrogen or C1-C15 saturated or unsaturated aliphatic hydrocarbon group, wherein 1 to 6 hydrogen atoms of C1-C15 saturated or unsaturated aliphatic hydrocarbon group may be substituted with a group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms independently selected nitrogen, oxygen or sulphur, and any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl, heteroarylalkenyl may be optionally substituted with lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhaloalkoxy (C1-C4), unsubstituted amino, N-lower alkylamino (C1-C4), or N-lower alkylamino carbonyl (C1-C4); b. Formula II is: (Formula Removed) or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein Ri' and R2' are independently selected from C1-C6 alkyl, C3-C7 cycloalkyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; and Z' represents oxygen or NR.3; wherein R3 represents hydrogen or C1-C3 alkyl; c. Formula III is, (Formula Removed) or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein R1" and R2" are independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; R3' represents C1C6 alkyl, wherein 1-3 hydrogen atom(s) may be substituted with a group independently selected from C5-C7 cycloalkyl, l,3-dioxo-l,3-dihydro-isoindolyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected C1-C4 alkyl or halogen; and Z represents oxygen or NR4', wherein R4' represents hydrogen or C1-C3 alkyl. The pharmaceutical compositions of each of the above aspects can include one or more of the following embodiments. For example, the one or more compounds of Formula I, II and Formula III can be selected from Compound No. 1 to Compound No. 150. Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or III described herein, a therapeutically effective amount of one or more B2-agonists, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more corticosteroids, one or more p38 MAP kinase inhibitors, one or more PDE-IV inhibitors or combinations thereof. Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or II described herein, a therapeutically effective amount of one or more corticosteroids, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more B2-agonists, one or more p38 MAP kinase inhibitors, one or more PDE-IV inhibitors or combinations thereof. Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or III described herein, a therapeutically effective amount of one or more p38 MAP kinase inhibitors, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more corticosteroids, one or more B2-agonists, one or more PDE-IV inhibitors or combinations thereof. Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or III described herein, a therapeutically effective amount of one or more PDE-IV inhibitors, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more corticosteroids, one or more B2-agonists, one or more p38 MAP kinase inhibitors or combinations thereof. Suitable B2-agonists as described herein may be any B2-agonist described in the art or subsequently discovered. For example, B2-agonists may include, but are not limited to, one or more compounds described in U.S. Patent Nos. 3,705,233; 3,644,353; 3,642,896; 3,700,681; 4,579,985; 3,994,974; 3,937,838; 4,419,364; 5,126,375; 5,243,076; 4,992,474; and 4,011,258, each of which are incorporated herein by reference. Examples of suitable B2-agonists include one or more of albuterol, salbutamol, biltolterol, pirbuterol, levosalbutamol, tulobuterol, terbutaline, bambuterol, metaproterenol, fenoterol, salmeterol, carmoterol, arformoterol, formoterol, and their pharmaceutically acceptable salts or solvates thereof or mixtures thereof. 3,436,389 3,947,478 4,290,962 5,482,934 6,723,713 3,992,534; 3,928,326 4,158,055; 4,298,604 4,472,393; 4,242,334 3,980,778 4,335,121 4,014,909 5,976,573 3,780,177 4,081,541 4,098,803 6,337,324 3,652,554; 4,226,862; 4,619,921; 6,057,307; Suitable corticosteroids as described herein may be any corticosteroid described in the art or subsequently discovered. For example, corticosteroids may include, but are not limited to, one or more compounds described in U.S. Patent Nos. 3,312,590; 3,983,233; 3,929,768; 3,721,687; 3,506,694; 3,639,434 4,076,708; 4,124,707 4,587,236; 4,472,392 5,837,699; 5,889,015; 5,278,156; 5,015,746 6,127,353; and 6,180,781, each of which are incorporated herein by reference. Examples of suitable corticosteroids include one or more of alclometasone, amcinonide, amelometasone, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, cloticasone, cyclomethasone, deflazacort, deprodone, dexbudesonide, diflorasone, difluprednate, fluticasone, flunisolide, halometasone, halopredone, hydrocortisone, hydrocortisone, methylprednisolone, mometasone, prednicarbate, prednisolone, rimexolone, tixocortol, triamcinolone, ulobetasol, and pharmaceutically acceptable salts, solvates thereof, or mixtures thereof. Suitable PDE-IV inhibitors may be any PDE-IV inhibitors described in the art or subsequently discovered. For example, PDE-IV inhibitors may include, but are not limited to, one or more compounds disclosed in WO 2005/021515, co-pending Indian Patent Application No. 303/DEL/2005; enprofylline, roflumilast, ariflo, Bay-198004, CP-325366 (WO 96/39408), BY343 (WO 98/21208), D-4396 (Sch-351591) (WO 00/26208), V-11294A, Z-15370 (WO 00/05218), and A WD-12-281 (WO 99/55696). Other examples of PDE-IV inhibitors include compounds selected from: 3-[3-{[(3.S)-l-Benzylpyrrolidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. la), 3-[2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]propan-l-ol (Compound No. 2a), [2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetonitrile (Compound No. 3a), 4-[(5S or 5R)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 4a), 4-[(5R or 5S)-l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 5a), 5-[(5S or 5R)-l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 6a), (5S or 5R)-3-(3,4-Dimethoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 7a), (5R or 5S)-3-(3,4-Dimethoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 8a), 2-(Benzyloxy)-4-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 9a), 2-[2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]ethanol (Compound No. 10a), 3-[4-(Difluoromethoxy)-3-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 1 la), 3-[3-(Cyclohexyloxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 12a), (5R or 5S)-3-[4-(Difluoromethoxy)-3-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 13a), (5S or 5R)-3-[4-(Difluoromethoxy)-3-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 14a), Ethyl [2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetate (Compound No. 15a), 3-[4-(Difluoromethoxy)-3-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 16a), 2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyI cyclohexanecarboxylate (Compound No. 17a), 5-[2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pentanoic acid (Compound No. 18a), 3-[3-(2,2,2-Trifluoroethoxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 19a), 3-[3-(Cyclopentylmethoxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 20a), /V-cyclopropyl-2-[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetamide (Compound No. 21a), 2-[2-(Difluoromethoxy)-5-( 1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetamide (Compound No. 22a), 2-[2-(Difluoromethoxy)-5-( 1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]-/V-methylacetamide (Compound No. 23a), 3-[3-(Cyclopentyloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 24a), 2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl cyclopropanecarboxylate (Compound No. 25a), 2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl morpholine-4-carboxylate (Compound No. 26a), 2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl benzoate (Compound No. 27a), 5-[2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy] pentanamide (Compound No. 28a), 3-[3-Propoxy-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 29a), 3-[3-lsopropoxy-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 30a), 3-[3-(Cyclopropylmethoxy)-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 31a), 3-[3-(2,3-Dihydro-l//-inden-2-yloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 32a), 5-(l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenol (Compound No. 33a), 3-[3-Methoxy-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 34a), 3-[3-Ethoxy-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 35a), 3-[3-Butoxy-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-enel0019955 (CompoundNo. 36a), 3-[3-(Cyclohexylmethoxy)-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 37a), 3-{[2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl} benzonitrile (Compound No. 38a), 2-{2-[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]ethyl}-l//-isoindole-l,3(2//)-dione (Compound No. 39a), 3-[3-(Cyclohexyloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 40a), Ethyl [5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy) phenoxyjacetate (Compound No. 41a), 3-[3-(CyclohexyImethoxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 42a), 7ert-butyl [2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetate (Compound No. 43a), N-cyclopropyl-2-[5-( 1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy) phenoxy]acetamide (Compound No. 44a), 2-(Cyclopentyloxy)-4-[(5R or 5S)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 45a), 2-(Cyclopentyloxy)-4-[(5S or 5R)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 46a), N-benzyl-2-[5-( 1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy) phenoxy]acetamide (Compound No. 47a), N-Cyclopentyl-2-[5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy) phenoxy]acetamide (Compound No. 48a), 7ert-butyl 4-[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy] piperidine-1-carboxylate (Compound No. 49a), Hydrochloride salt of 3-[4-(difluoromethoxy)-3-(piperidin-4-yloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 50a), 3-{3-[(l-Acetylpiperidin-4-yl)oxy]-4-(difluoromethoxy)phenyl}-l,7-dioxa-2-azaspiro [4.4]non-2-ene (Compound No. 51a), 7ert-butyl (3S)-3-[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pyrrolidine-l-carboxylate (Compound No. 52a), 7ert-butyl (3R)-3-[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pyrrolidine-l-carboxylate (Compound No. 53a), 7ert-butyl 3-[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidine-l-carboxylate (Compound No. 54a), 7ert-butyl (2S)-2-{[2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl}pyrrolidine-l- carboxylate (Compound No. 55a), (5R or 5S)-3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 56a), (5S or 5R)-3-(3-isopropoxy-4-methoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 57a), (5S or 5R)-3-[3-(Cyclopropylmethoxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 58a), 2-(Cyclopropylmethoxy)-4-[(5S or 5R)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 59a), 4-[(5S or 5R)-l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-isopropoxyphenol (Compound No. 60a), (5S or 5R)-3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 61a), (5S or 5R)-3-[3-(Cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 62a), (5S or 5R)-3-[4-(difluoromethoxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 63a), (5R or 5S)-3-[4-(difluoromethoxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 64a), 2-(Cyclopropylmethoxy)-4-[(5R or 5S)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 65a), 4-[(5R or 5S)-l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-isopropoxyphenol (Compound No. 66a), (5R or 5S)-3-[3-(Cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 67a), (5R or 5S)-3-[4-(difluoromethoxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 68a), Hydrochloride salt of 3-{4-(difluoromethoxy)-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 69a), Hydrochloride salt of 3-{4-(difluoromethoxy)-3-[(2S)-pyrrolidin-2-ylmethoxy]phenyl}-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 70a), Hydrochloride salt of 3-{4-(difluoromethoxy)-3-[(27?)-pyrrolidin-2-ylmethoxy]phenyl}-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 71a), 3-[4-(Difluoromethoxy)-3-{[(2/?)-l-propionylpyrrolidin-2-yl]methoxy}phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 72a), 3-[3-{[(2,5)-l-acetylpyrrolidin-2-yl]methoxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 73a), 3-[3-{[(3S)-l-benzoylpyrrolidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 74a), 3-[4-(Difluoromethoxy)-3-{[(3S)-l-propionylpyrrolidin-3-yl]oxy}phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 75a), (5S or 5R)-3-[3-(BenzyIoxy)-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 76a), 2-(Benzyloxy)-4-[(5S or 5R)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 77a), (5S or 5R)-3-[3-(Benzyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 78a), 3-{4-(Difluoromethoxy)-3-[(1-propionylpiperidin-4-yl)oxy]phenyl}-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 79a), 3-[4-(Ditluoromethoxy)-3-{[l-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 80a), 3-[3-{[l-(Cyclopropylcarbonyl)piperidin-4-yl]oxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 81a), 3-[3-{[l-(Cyclopentylcarbonyl)piperidin-4-yl]oxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 82a), 3-[4-(Difluoromethoxy)-3-({l-[(trifluoromethyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 83a), 3-{3-[(l-Acetylpiperidin-3-yl)oxy]-4-(difluoromethoxy)phenyl}-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 84a), 3-{4-(Difluoromethoxy)-3-[(l-propionylpiperidin-3-yl)oxy]phenyl}-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 85a), 3-[4-(Difluoromethoxy)-3-{[l-(4-fluorobenzoyl)piperidin-3-yl]oxy}phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 86a), 17 3-[3-{[l-(Cyclopropylcarbonyl)piperidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 87a), 3-[3-{[l-(Cyclopentylcarbonyl)piperidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 88a), 3-[4-(Difluoromethoxy)-3-{[l-(ethylsulfonyl)piperidin-3-yl]oxy}phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 89a), 3-[3-(Benzyloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 90a), 2-(Difluoromethoxy)-5-[(55 or 5R)-l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 91a), 5-[(5R or 5S)-l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 92a) and any pharmaceutically acceptable acid addition salts thereof. Other suitable PDE-IV inhibitors (disclosed in co-pending Indian Patent Application No. 303/DEL/2005) include, for example: 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-en-6-ol (Compound No. laa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyll-N-fluorophenyl)-l-oxa-2,7-diazaspiro[4.4]lnon-2-ene-7--carboxamide (Compound No. 2aa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-(tetrahydrofuran-3-ylcarbonyl)-l-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 3aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-A',A'-dimethyl-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7-sulfonamide (Compound No. 4aa), A'-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide (Compound No. 5aa), 2-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-en-7-yl}acetamide (Compound No. 6aa), Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-prolyl-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 7aa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-morpholin-4-yl-ethyl)-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 8aa), A'-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide (Compound No. 9aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-(methylsulfonyl)-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 10aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.4]non-2-ene (Compound No. 1 laa), 3-[3,4-bis(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 12aa), 3-(3,4-diisopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 13aa), 3-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 14aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-en-8-one (Compound No. 15aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-en-8-ol (Compound No. 16aa),. 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-isopropyl-l-oxa-2, 7-diazaspiro [4.4] non-2-ene (Compound No. 17aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-7-(cyclopropylcarbonyl)-l-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 18aa), /V-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide (Compound No. 19aa), 7-acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 20aa), Tert-buly 1 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1 -oxa-2,7-diazaspiro[4.5]dec-2-ene-7-carboxylate (Compound No. 2 laa), N-butyl-A"-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl}urea (Compound No. 22aa), N-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl}-N-(2-methoxyphenyl)urea (Compound No. 23aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-ol (Compound No. 24 Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.5]dec-2-ene (Compound No. 25aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-one (Compound No. 26aa), 3-[3,4-bis(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 27aa), 3-[3,4-Bis(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 28aa), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l ,7-dioxa-2-azaspiro[4.4]non-2-en-4-ol (Compound No. 29aa), (R)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 30aa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(cyclopropylmethyl)-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 3 laa). N-Benzyl-3-[3-(cycIopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide (Compound No. 32aa), 3-[3,4-Bis(benzyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 33aa), 4-(l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)benzene-l,2-diol (Compound No. 34aa), 7-Amino-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-en-6-one (Compound No. 35aa), Ethyl 8-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene-4-carboxylate (Compound No. 36aa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylic acid (Compound no. 37aa), 8-Benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 38aa), Ethyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylate (Compound No. 39aa), 3-[3-(Difluoromethoxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 40aa), 2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 41aa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-en-6-one (Compound No. 42aa),. 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,6a-dimethyl-3aH-cyclopenta[d]isoxazole-4,6(5H,6aH)-dione (Compound No. 43aa), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazole (Compound No. 44aa),. 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-6,6a-dihydrofuro[3,4-c(]isoxazol-4(3aH)-one (Compound No. 45aa), Tert-buty\ [({3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl}amino)carbonyl]carbamate (Compound No. 46aa), N-{3-[3Cyclopentyloxy-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec2-en-8-yl}cyclopentanecarboxamide (Compound No. 47aa), 8-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 48aa), 8-(Cyclopentylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 49aa), 3-[3-(CyclopentyIoxy)-4-methoxyphenyl]-8-(2-piperidin-l-ylethyl)-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 50aa), 3-(2,3-Dihydro-l,4-benzodioxin-6-yl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 51aa), 3-[3-(CyclopentyIoxy)-4-methoxyphenyl]-l,8-dioxa-2-azaspiro[4.5]dec-2-ene (Compound No. 52aa), 3-[3-(CyclopentyIoxy)-4-methoxyphenyl]-3aH-cyclopenta[0.05) Tablel: Potency of the compounds for relaxing carbachol / precontracted guinea-pig isolated trachea (Table Removed) n : number of experiments; * : (p<0.05) vs 14016; ns: (p>0.05) vs Rolipram; @ : (p<0.()l) vs Roflumilast C No. 66 and C No. 124aa refers to Compound No. 66 and 124aa, respectively. (Figure Removed) -Log[Rolipram] Relaxant activity of C No.i24aaroflumilast & rolipram in guinea pig trachea pre-contracted with carbachol in the presence ofC No. 66 Example 2. In-vivo assay to evaluate efficacy of MRA in combination with PDE-IV inhibitors Drug treatment:MRA (lng/kg to lmg/kg) and PDE-IV inhibitor (lng/kg to lmg/kg) were instilled intratracheally under anesthesia either alone or in combination. Method:Wistar rats weighing 200±20gm were used in the study. Rats had free access to food and water. On the day of experiment, animals were exposed to lipopolysaccharide (LPS, lOOug/ml) for 40 min. One group of vehicle treated rats was exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals were placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing concentration of acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone. The respiratory parameters were recorded online using Biosystem XA software, (Buxco Electronics, USA). Penh, at any chosen dose of acetylcholine was, expressed as percent of PBS response and the using a nonlinear regression analysis PC 100 (2 folds of PBS value) values computed. A synergistic effect was observed with the combination of muscarinic receptor antagonist (MRA) with PDE 4 inhibitor which can be seen from below mentioned graphs. (Figure Removed) LPS Vehicle C No. 66 C No. 124aa (6ng) C No. 124aa (6|jg) PBS Vehicle (0.01pg) + CNo. 66- (0.01pg) • C No. 66 refers to Compound No. 66 • C No. 124aa refers to Compound No. 124aa • Combining C No. 124aa (PDEIV inhibitor) - 6ug and C No. 66 (MRA)-10 ng Example 3.ln-vivo assay to evaluate efficacy of MRA in combination with Corticosteroids results in synergistic effect Ovalbumin induced early phase bronchoconstriction and airway inflammation: Guinea pigs are sensitised on days 0, 7 and 14 with 50-\ig ovalbumin and 10 mg aluminium hydroxide injected intraperitoneally. On days 19 and 20 guinea pigs are exposed to 0.1% w v" ovalbumin or PBS for 10 min, and with 1% ovalbumin for 30 min on day 21. Guinea pigs are treated with test compound or standard or vehicle once daily from day 19 and continued for 4 days. Ovalbumin induced early phase bronchoconstriction : On day 21, after drug or vehicle administration, basal respiratory parameters are recorded using Whole body Plethysmograph (Biosystem XA software, Buxco Electronics, USA) followed by challenge with 1% ovalbumin/PBS for 10 min duration. For recording basal respiratory parameters, 10 consecutive 1 min readings are averaged. Each 1 min. reading represents an average of each breadth taken in that 60 sec duration. Following PBS/Ovalbumin challenge data is recorded for 120 min, which represented hundred and twenty recordings one min apart. Each 1 min recording is an average of all the breath in 1 min. PenH, at any chosen time point post challenge is expressed as percent of basal response. These values are plotted against time using Graphpad prism software (GraphPad Software Inc, USA) and Area Under the Curve (AUC) is computed. Percent inhibition is computed using the following formula. (Formula Removed) Where, AUCOVA = AUC in vehicle treated group challenged with ovalbumin AUCTEST = AUC in group treated with a given dose of test compound AUCPBS = AUC in vehicle treated group challenged with PBS Ovalbumin induced airway inflammation 24 hrs after the final ovalbumin challenge BAL is performed using Hank's balanced salt solution (HBSS). Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in 1ml HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and eosinophil count are expressed as cell count (millions cells ml*1 of BAL). Eosinophil is also expressed as percent of total leukocyte count. % inhibition is computed using the following formula. (Formula Removed) Where, EOSOVA = Percentage of eosinophil in vehicle treated group challenged with ovalbumin Eos ] LST =Percentage of eosinophil in group treated with a given dose of test compound EOSCON = Percentage of eosinophil in vehicle treated group challenged with PBS. Example 4. In-vivo assay to evaluate efficacy of "MRA" in combination with p38 MAP kinase inhibitors Lipopolysaccharide (LPS) induced airway hyperreactivity (AHR) and neutrophilia: Drug treatment:MRA (lng/kg to lmg/kg) and p38 MAP kinase inhibitor (lng/kg to lmg/kg) are instilled intratracheally under anesthesia either alone or in combination. Method:Male wistar rats weighing 200±20gm are used in the study. Rats have free access to food and water. On the day of experiment, animals are exposed to lipopolysaccharide (LPS, 100(ig/ml) for 40 min. One group of vehicle treated rats is exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals are placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone. The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA). Penh, at any chosen dose of acetylcholine is, expressed as percent of PBS response and the using a nonlinear regression analysis PC 100 (2 folds of PBS value) values are computed. Percent inhibition is computed using the following formula. (Formula Removed) Where, PC100LPS = PC 100 in vehicle treated group challenged group with LPS PC100TEST = PC 100 in group treated with a given dose of test compound PC100PBS = PC 100 in vehicle treated group challenged with PBS Immediately after the airway hyperreactivity response is recorded, animals are sacrificed and bronchoalveolar lavage (BAL) is performed. Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in 1ml HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and Neutrophil counts are expressed as cell count (millions cells ml"' of BAL). Percent inhibition is computed using the following formula. (Formula Removed) Where, NC[,ps = Percentage of neutrophil in vehicle treated group challenged with LPS NCTHST =Percentage of neutrophil in group treated with a given dose of test compound NCPBS = Percentage of neutrophil in vehicle treated group challenged with PBS The percent inhibition data is used to compute ED50 vales using Graph Pad Prism software (Graphpad Software Inc., USA). Example 5. In-vivo assay to evaluate efficacy of "MRA" in combination with (32-agonists Drug treatment: MRA (lng/kg to lmg/kg) and long acting P2 agonist are instilled intratracheally under anesthesia either alone or in combination. Method: Wistar rats (250-350gm) or balb/C mice (20-30gm) are placed in body box of a whole body plethysmograph (Buxco Electronics., USA) to induce bronchoconstriction. Animals are allowed to acclimatise in the body box and are given successive challenges, each of 2 min duration, with PBS (vehicle for acetylcholine) or acetylcholine (i.e. 24, 48, 96, 144, 384, and 768 mg/ml). The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA) for 3 min. A gap of 2 min is allowed for the animals to recover and then challenged with the next higher dose of acetylcholine (ACh). This step is repeated until Penh of rats attained 2 times the value (PC-100) seen with PBS challenge. Following PBS/ACh challenge, Penh values (index of airway resistance) in each rat/mice is obtained in the presence of PBS and different doses of ACh. Penh, at any chosen dose of ACh is, expressed as percent of PBS response. The Penh values thus calculated are fed into Graph Pad Prism software (Graphpad Software Inc.,USA) and using a nonlinear regression analysis PC 100 (2 folds of PBS value) values are computed. Percent inhibition is computed using the following formula. (Formula Removed) Where, PC 100 CON = PC 100 in vehicle treated group PC100IHST = PC 100 in group treated with a given dose of test compound 768 = is the maximum amount of acetylcholine used. WE CLAIM: 1. A pharmaceutical composition comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids, anticholinergics, dopamine agonists, antiallergics, PAF antagonists, leukotriene antagonists, EGFR kinase inhibitors, different muscarinic receptor antagonists or a mixture thereof, wherein the MRA is one or more compounds having the structures of Formula I, II, or III, wherein: a. Formula I is: (Formula Removed) Formula I or a pharmaceutical^ acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein Ar represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, sulphur or nitrogen, wherein the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4), N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; Ri represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen {e.g., fluorine, chlorine, bromine and iodine); R2 represents alkyl, (C3-C7) cycloalkyl ring, (C3-C7) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4) or N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; W represents (CH2)P, wherein p represents 0 to 1; X represents oxygen, sulphur, -NR or no atom (i.e., a bond), wherein R represents hydrogen or (Ci-6) alkyl; Y represents CHR5CO or (CH2)q, wherein R5 represents hydrogen or methyl, and q represents 0to4; Z represents oxygen, sulphur, or NR10, wherein Rio represents hydrogen, or C1.6 alkyl; Q represents (CH2)n, CHRs or CH2CHR9, wherein n represents 0 to 4, R8 represents H, OH, C1-6, alkyl, C1-6 alkenycol,, or C1-6 alkoxy, and R9 represents H, OH, lower alkyl (C1-C4) or lower alkoxy (C1-C4); R6 and R7 are independently selected from H, CH3, COOH, CONH2, NH2 or CH2NH2; and R4 represents hydrogen or C1-C15 saturated or unsaturated aliphatic hydrocarbon group,wherein 1 to 6 hydrogen atoms of C1-C15 saturated or unsaturated aliphatic hydrocarbon group may be substituted with a group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms independently selected nitrogen, oxygen or sulphur, and any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl, heteroarylalkenyl may be optionally substituted with lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhaloalkoxy (C1-C4), unsubstituted amino, N-lower alkylamino (C1-C4), or N-lower alkylamino carbonyl (C1-C4); b. Formula II is: (Formula Removed) or a pharmaceutical^ acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein R1' and R2' are independently selected from C1-C6 alkyl, C3-C7 cycloalkyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; and Z' represents oxygen or NR3, wherein R3 represents hydrogen or C1-C3 alkyl; c. Formula III is, (Formula Removed) or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein R1" and R2" are independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; R3' represents C1-C6 alkyl, wherein 1-3 hydrogen atom(s) may be substituted with a group independently selected from C5-C7 cycloalkyl, l,3-dioxo-l,3-dihydro-isoindolyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected C1-C4 alkyl or halogen; and Z represents oxygen or NR4', wherein R4' represents hydrogen or C1-C3 alkyl. 2. The pharmaceutical composition of claim 1, wherein the one or more MRA are selected from: (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 1) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 2) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 3) (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 4) (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 5) (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 6) (la,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 7) (la,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 8) (la,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 9) (la,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 10) (la,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 11) (la,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 12) (la,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 13) (la,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 14) (la,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 15) (1 a, 5 a,6a)-N- [3 -(4-methyl-3 -pentenyl)-3 -azabicyclo [3.1.0]hexyl-6-(aminomethyl)-yl] -2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 16) (la,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 17) (la,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 18) (la,5a,6a)-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 19) (la,5a,6a)-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 20) (la,5a,6a)-N-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 21) (la,5a,6a)-N-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 22) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(l-aminoethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 23) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(l-aminoethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 24) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(l-aminoethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 25) (la,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 26) (la,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 27) (2R)-(+)- (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 28) (2R)-(+)- (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 29) (2R) (+)-(la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 30) (2R) (+)-(la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate(Compound No. 31) (2S)-(-)- (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 32) (2S)-(-)-(la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 33) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt (Compound No. 34) (2R)-(+)- (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 35) (2R)-(+)- (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 36) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound No. 37) (la,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopropyl-2-phenyl acetamide (Compound No. 38) (la,5a,6a)-N-[ 3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 39) (la,5a,6a)-[ 3-(3,4- methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 40) (la,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L-(+)-tartrate salt (Compound No. 41) (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2 diphenyl acetate L(+)-tartrate salt (Compound No. 42) (la,5a,6a)- [3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)-tartrate salt (Compound No. 43) (la,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt (Compound No. 44) (la,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 45) (1 a, 5 a,6a)-N - [3 -(4-pyridy lmethyl)-3 -azabicyclo [3.1.0]hexy l-6-(aminomethyl)-yl] -2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 46) (la,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 47) (la,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide(Compound No. 48) (la,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 49) (la,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 50) (la,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 51) (1 a,5a,6a)-N- [3 -(2-pyridylmethyl)-3 -azabicyclo [3.1.0]hexyl-6-(aminomethyl)-yl] -2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 52) (la,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 53) (la,5a,6a)-N-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 54) (la,5a,6a)-N-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 55) (la,5a,6a)-N-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 56) (la,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 57) (la,5a.6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 58) (la.5a,6a)-[3-(l-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 59) (la,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide .hydrochloride salt (Compound No. 60) (la,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L(-) malic acid salt (Compound No. 61) (la,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. maleate salt (Compound No. 62) (2R,2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 63) (2R,2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 64) (2R)-(la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide (Compound No. 65) (2R)-(la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound No. 66) (2S)-(la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide (Compound No. 67) (2S)-(la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound No. 68) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 69) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide (Compound No. 70) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound No. 71) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide tartarate salt (Compound No. 72) (2R) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound No. 73) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide (Compound No. 74) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3- difluorocyclopentyl)-2-phenyl acetamide (Compound No. 75) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3- difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound No. 76) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 77) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 78) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2- phenyl acetamide (Compound No. 79) (2R, 2S) (la,5a,6a)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl)-2-cyclopentyl-2- hydroxy-N-methyl-2- phenyl acetamide (Compound No. 80) N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 81) N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2Tphenyl-2-hydroxy-2-(N-methyl) phenylacetamide tartarate salt (Compound No. 82) (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2- phenylacetamide (Compound No. 83) (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2- phenylacetamide hydrochloride salt (Compound No. 84) (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenyl acetamide (Compound No. 85) (2R, 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetic acid (Compound No. 86) (2R)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 87) (2R)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 88) (2R, 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 89) (2R, 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 90) (2R, 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 91) (2R, 2S)-N-[(lcc, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetamide (Compound No. 92) (2R)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 93) (2R, 2S)-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(m-methylphenyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 94) (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-phenylacetamide (Compound No. 95) (2R, 2S)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-phenylacetamide (Compound No. 96) (2R)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 97) (2R)-N-[(la, 5a, 6a)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 98) (2R, 2S) (la, 5a, 6a)-N- {-[4-(l,3-dioxo-l, 3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo [3.1.0] hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 99) (2R) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopent-l-enyl-2-phenylacetamide (Compound No. 100) (2R, 2S) (la, 5a, 6a)-N-(3-Isopropyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 101) (2R, 2S) (la, 5a, 6a)-N-(3-Diphenylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 102) (2R, 2S) (la, 5a, 6a)-N-(3-sec-butyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyI-2-phenylacetamide (Compound No. 103) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-pentyl)-2-phenylacetamide (Compound No. 104) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-2-(4-methoxyphenyl) acetamide (Compound No. 105) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-(N-ethyl)-2-phenylacetamide (Compound No. 106) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-ethyl)-2-phenylacetamide (Compound No. 107) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-(N-ethyl)-2-phenylacetamide (Compound No. 108) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)- 2-hydroxy-2-(3-pentyl)-(N-methyl)-2-phenylacetamide (Compound No. 109) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(sec-butyl)-(N-methyl)-2-phenylacetamide (Compound No. 110) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-(N-methyl)-2-phenylacetamide (CompoundNo. Ill) (2R, 2S) (la, 5a, 6a)-N-[3-(4-tert-butyl-benzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 112) (2R, 2S) (la, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohex-2-enyl-2-phenylacetamide (Compound No. 113) (1 a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 114) (2R, 2S) (la, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 115) (2R, 2S) (la, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 116) (la, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 117) (la, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 118) (2R, 2S) (la, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 119) (2R, 2S) (la, 5a, 6a)-N-[2-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 120) (la, 5a, 6a)-N-[3-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 121) (2R, 2S) (la, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 122) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-2-phenylacetamide (Compound No. 123) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 124) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 125) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenyl acetic acid ester (Compound No. 126) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-(N-methyl)-2-phenylacetamide (Compound No. 127) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenylacetamide (Compound No. 128) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 129) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenyl acetic acid ester (Compound No. 130) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester (Compound No. 131) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester tartarate salt (Compound No. 132) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide (Compound No. 133) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide tartarate salt (Compound No. 134) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2,2-di(4-fluorophenyl)acetic acid ester (Compound No. 135) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-di(4-fluorophenyl)-acetamide (Compound No. 136) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclobutyl-2-phenyl acetic acid ester (Compound No. 137) (2R, 2S) (la, 5a, 6a)-N-(3-cyclohexylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 138) (2R) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-methyl)-2-phenylacetamide (Compound No. 139) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-(4-methylphenyl) acetamide (Compound No. 140) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-2-(4-methylphenyl) acetic acid ester (Compound No. 141) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-2-phenyl acetic acid ester (Compound No. 142) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-methyl-2-phenyl acetamide (Compound No. 143) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-2-phenyl acetic acid ester (Compound No. 144) (la, 5a, 6a)-N-(3-methyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-phenyl-(N-methyl)-2-phenylacetamide (Compound No. 145) (la, 5a, 6a)-N- (3-benzyl-3-azabicyclo [3.1.0] hex-6-yl-methyl]-2-hydroxy-2, 2-di (3-methylphenyl) acetamide (Compound No. 146) (2R, 2S) (la, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-(3-pentyl)-2-phenyl acetic acid ester (Compound No. 147) (2R, 2S) (la, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-(N-methyl)-2-phenylacetamide (Compound No. 148) N-[(la,5a,6a)-3-azabicyclo[3.1.0.]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide hydrochloride (Compound No. 149), or Tartarate salt of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)2-thienylacetate (Compound No. 150). 3. A method of treating or preventing autoimmune, inflammatory, or allergic disorders, wherein the method comprises administering to a mammal in need thereof a pharmaceutical composition comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids, anticholinergics, dopamine agonists, antiallergics, PAF antagonists, leukotriene antagonists, EGFR kinase inhibitors, different muscarinic receptor antagonists or a mixture thereof, wherein the MRA has the structures of Formula I, II, or III, wherein a. Formula I is: (Formula Removed) Formula I or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein Ar represents an aryl or a heteroaryl ring having 1 -2 heteroatoms independently selected from oxygen, sulphur or nitrogen, wherein the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4), N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; Ri represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy. carbamoyl or halogen (e.g., fluorine, chlorine, bromine and iodine); R2 represents alkyl, (C3-C7) cycloalkyl ring, (C3-C7) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhalo alkoxy (C1-C4), unsubstituted amino, N-lower alkyl (C1-C4) or N-aryl amino, amino carbonyl, N-lower alkyl (C1-C4) or N-aryl amino carbonyl; W represents (CH2)P, wherein p represents 0 to 1; X represents oxygen, sulphur, -NR or no atom (i.e., a bond), wherein R represents hydrogen or (Ci-6) alkyl; Y represents CHR5CO or (CH2)q, wherein R5 represents hydrogen or methyl, and q represents 0 to 4; Z represents oxygen, sulphur, or NR10, wherein Ri0 represents hydrogen, or Ci_6 alkyl; Q represents (CH2)n, CHRg or CH2CHR9, wherein n represents 0 to 4, R8 represents H, OH, C1-6, alkyl, C1-6 alkenyl, or C1-6 alkoxy, and R9 represents H, OH, lower alkyl (C1-C4) or lower alkoxy (C1-C4); R6 and R7 are independently selected from H, CH3, COOH, CONH2, NH2 or CH2NH2; and R4 represents hydrogen or C1-C15 saturated or unsaturated aliphatic hydrocarbon group, wherein 1 to 6 hydrogen atoms of C1-C15 saturated or unsaturated aliphatic hydrocarbon group may be substituted with a group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms independently selected nitrogen, oxygen or sulphur, and any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl, heteroarylalkenyl may be optionally substituted with lower alkyl (C1-C4), lower perhalo alkyl (C1-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C1-C4), lower perhaloalkoxy (C1-C4), unsubstituted amino, N-lower alkylamino (C1-C4), or N-lower alkylamino carbonyl (C1-C4); b. Formula II is: (Formula Removed)or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein Ri' and R2' are independently selected from C1-C6 alkyl, C3-C7 cycloalkyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; and Z' represents oxygen or NR3, wherein R3 represents hydrogen or C1-C3 alkyl; c. Formula III is, (Formula Removed) or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein 49 Ri" and R2" are independently selected from C|-C6alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy or halogen; R3' represents C1-C6 alkyl, wherein 1-3 hydrogen atom(s) may be substituted with a group independently selected from C5-C7 cycloalkyl, l,3-dioxo-l,3-dihydro-isoindolyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected C1-C4 alkyl or halogen; and Z represents oxygen or NR4', wherein R4' represents hydrogen or C1-C3 alkyl.